GSK: to license hepatitis B program from Ionis
(CercleFinance.com) - US biotech firm Ionis has licensed its experimental hepatitis B drug program to GSK for 25 million dollars upfront, with potential milestone payments of up to 262 million dollars.
Following positive Phase 2 results, GSK today exercised its option to license Ionis's antisense medicines for people with the chronic hepatitis B virus infection.
Hepatitis B is a chronic viral infection of the liver that is potentially fatal, resulting in either cirrhosis, liver failure or liver cancer.
There are over 200 million patients worldwide living with the disease.
Copyright (c) 2019 CercleFinance.com. All rights reserved.